Opinion on Pharmaceuticals and Healthcare in Asia-Pacific

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Yamanouchi/Fujisawa: still some way from world domination

The relatively small size of Japanese pharma players means that independent overseas growth can only take them so far, with international subsidiaries lacking the scale to promote a blockbuster drug. The tie up of Yamanouchi and Fujisawa represents the first step towards a global mega-player, but further partnerships will be essential to enter the top tier of global pharma companies.

Published By Datamonitor
25 Feb 2004
CommentWire
CommentWire

Yamanouchi / Fujisawa: a stellar future

Yamanouchi [4503.TO] and Fujisawa [4511.TO] have revealed that their post-merger company will be known as Astellas. The combined company is expected to become Japan's largest pharmaceutical company, with cardiovascular and AIID products expected to drive growth in the medium term. Although Astellas will face stiff competition, it should prove a good move for both firms.

Published By Datamonitor
26 May 2004
Expert View
Expert View

Xigris: Lilly's sepsis flop misses out

Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?

Published By Datamonitor
22 Mar 2002
Expert View
Expert View

Xarelto data raise questions at the 2010 American Heart Association Scientific Sessions

Results from the ROCKET-AF trial of Xarelto in stroke prevention in atrial fibrillation have been presented at this year's Scientific Sessions of the American Heart Association. While positive, the data show that Xarelto has by no means outperformed Pradaxa. Clinicians may start to see the two drugs as complementary alternatives, based on their respective performance in various subgroups.

Published By Datamonitor
16 Nov 2010
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
Expert View
Expert View

World Vaccines Conference Asia: successful penetration strategies are key

In light of the current H1N1 influenza outbreak, the first day of the World Vaccine Congress Asia held in Singapore was dedicated to influenza vaccines. Asia is currently an underserved market, despite significant disease burden, and given the right strategies for market entry, it could evolve into an attractive opportunity for Western flu vaccine producers.

Published By Datamonitor
18 Jun 2009
Expert View
Expert View

World Vaccine Congress Asia: vast regional diversity requires flexibility and targeted portfolios

Spanning one third of the globe's circumference and home to more than half of the world's population, the Asia Pacific region is incredibly diverse. This year's World Vaccine Congress Asia highlighted the enormous variation in the vaccine landscape in the region, owing to a myriad of political, cultural, economic and geographic differences.

Published By Datamonitor
24 Jun 2009
Expert View
Expert View

World Vaccine Congress Asia: new partnerships open doors to regional markets

At the World Vaccine Congress Asia, it became apparent that new local facilities and partnerships are essential to expand supply, thus providing openings into the emerging vaccine markets of the region. GlaxoSmithKline and Sanofi Pasteur are leading in the space, overcoming low levels of disease awareness and financial shortages to secure a strong foothold in Asia.

Published By Datamonitor
24 Jun 2009
Expert View
Expert View

World Congress on Osteoporosis highlights changing face of bone health

Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.

Published By Datamonitor
18 May 2010
ResearchWire
ResearchWire

Women's health: 7.2 million PCOS sufferers in the US

Published By Datamonitor
08 May 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.